Amedisys Inc (AMED) Director Bruce D. Perkins Buys 2,000 Shares of Stock
Amedisys Inc (NASDAQ:AMED) Director Bruce D. Perkins bought 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was purchased at an average cost of $46.60 per share, with a total value of $93,200.00. Following the completion of the transaction, the director now directly owns 15,825 shares in the company, valued at $737,445. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of Amedisys Inc (NASDAQ AMED) traded up 3.21% during mid-day trading on Friday, reaching $48.56. The company’s stock had a trading volume of 440,765 shares. The company has a 50-day moving average of $59.50 and a 200-day moving average of $54.23. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91. The company has a market cap of $1.64 billion, a P/E ratio of 41.50 and a beta of 0.89.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.42 earnings per share. Equities research analysts forecast that Amedisys Inc will post $2.21 earnings per share for the current fiscal year.
A number of brokerages recently commented on AMED. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Wednesday, July 26th. Stephens boosted their price objective on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a report on Thursday, May 4th. Zacks Investment Research lowered Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, April 18th. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 12th. Finally, Royal Bank Of Canada reissued a “hold” rating and set a $56.00 price objective on shares of Amedisys in a report on Monday, June 5th. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company. Amedisys currently has a consensus rating of “Buy” and a consensus target price of $56.50.
Several large investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Amedisys by 2,877.7% in the first quarter. BlackRock Inc. now owns 5,676,870 shares of the health services provider’s stock valued at $290,032,000 after buying an additional 5,486,225 shares during the period. Vanguard Group Inc. increased its stake in shares of Amedisys by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,369,678 shares of the health services provider’s stock valued at $121,067,000 after buying an additional 63,238 shares during the period. FMR LLC increased its stake in shares of Amedisys by 6.9% in the first quarter. FMR LLC now owns 2,352,632 shares of the health services provider’s stock valued at $120,196,000 after buying an additional 152,632 shares during the period. William Blair Investment Management LLC increased its stake in shares of Amedisys by 8.1% in the first quarter. William Blair Investment Management LLC now owns 1,632,242 shares of the health services provider’s stock valued at $83,391,000 after buying an additional 122,305 shares during the period. Finally, American Century Companies Inc. increased its stake in shares of Amedisys by 148.7% in the first quarter. American Century Companies Inc. now owns 1,200,754 shares of the health services provider’s stock valued at $61,347,000 after buying an additional 717,939 shares during the period. 97.81% of the stock is owned by institutional investors.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.